Brokerage reports Salomon Smith Barney ~ August 27, 2001 Biopure Corporation (BPUR)# BPUR: Achieves Primary Safety Endpoint In US Pivotal 1S (Buy, Speculative) Study -- Very Good News Mkt Cap: $499.5 mil. August 27, 2001 SUMMARY * Biopure said it achieved the primary safety endpoint MEDICAL SUPPLIES & in the U.S. Phase III trial of Hemopure in 693 patients TECHNOLOGY undergoing elective orthopaedic surgery. The primary Phil Nalbone safety endpoint related to whether Hemopure had a worse overall safety profile compared with donated human red blood cell transfusions. Sam Chang * Biopure said statistical analysis of the trial data show that the overall medical risk to patients receiving Hemopure was no worse than the risk to patients Jenny Hsui receiving blood. * The attainment of the primary safety endpoint is the most important milestone to date in the development of Biopure. This news gives us renewed confidence that Hemopure has a rich medical and commercial future. * Hemopure appears to meet the two criteria for achieving regulatory approval -- both safety and efficacy. On May 8, Biopure reported that the product exceeded the primary efficacy endpoint. OPINION Biopure Corp. announced today that it achieved the primary safety endpoint in the pivotal U.S. Phase III clinical trial of its oxygen therapeutic, Hemopure. The pivotal study evaluated 693 patients undergoing elective orthopaedic surgery. The patients were randomized to treatment with either Hemopure or donated human red blood cells. In our opinion, this is the most significant milestone to date in the development of Hemopure. We now know that Hemopure appears to meet the two criteria necessary to achieve regulatory approval -- both safety and efficacy. Biopure said on May 8 that Hemopure exceeded the primary efficacy endpoint in the pivotal trial. Together, these two elements give us confidence that Hemopure has a promising medical and commercial future, particularly as the worldwide shortage of donor blood becomes more severe. We are reiterating our 1S (Buy, Speculative) rating on Biopure.
SEC filings - 8K Outback enters the seafood business Tampa, FL -- August 27, 2001 -- Outback Steakhouse, Inc. (NYSE - OSI) which operates 819 casual and upscale casual restaurants internationally, and Bonefish Grill Restaurants which operates two casual restaurants in the Tampa Bay area co- announced today that they have entered into an agreement in principle to co-develop future Bonefish Grills. Founded in January of 2000 in St. Petersburg, Florida by veteran restaurateurs Tim Curci and Chris Parker, Bonefish Grill features a stellar collection of finfish -- cooked over an oak- burning grill -- hand-cut beef, and pasta and chicken dishes each with its own enhanced flavors. Outback Steakhouse, Inc. operates 708 Outback Steakhouses, 93 Carrabba's Italian Grills, seven Fleming's Prime Steakhouse & Wine Bars, eight Roy's and one Lee Roy Selmon's in 49 states and 19 countries internationally. Ford -- implications of recall … We have preliminarily agreed to bear a portion of the costs of Firestone's recall. In addition, we have suspended production of Explorer, Mountaineer, Ranger and B Series models for the two-week period beginning August 28, 2000, which will allow us to divert about 70,000 replacement tires for use in the recall. Although we expect these actions to reduce revenues and increase costs, it is too early to assess their overall financial impact in the second half of 2000. At this point, neither Ford nor Firestone has determined the root cause of any defect in the affected tires. The National Highway Traffic Safety Administration ("NHTSA") is investigating this matter and could conclude that the recall should be expanded to include other Firestone tires. On September 1, 2000, NHTSA released a Consumer Advisory, suggesting the scope of the recall could be expanded and recommending that owners of vehicles with certain models and sizes of Firestone tires not already being recalled take a number of actions to enhance their safety.